Clinical Trial Update: Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab plus bevacizumab and chemotherapy for non-small cell lung cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Non-squamous NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING